MicroPort® CardioFlow Completes Five Pre-Market Implantations of VitaFlow Liberty® in Denmark

Copenhagen, Denmark, 20 November 2023 — Recently, the VitaFlow Liberty®Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty®), developed by MicroPort® CardioFlow, completed five pre-market implantations at Rigshospitalet (RH), Copenhagen University Hospital in Denmark.

These procedures were performed by cardiology expert Dr Ole De Backer and his team from RH, with Irish cardiology specialist Dr Darren Mylotte participating as the guiding expert. The valves were appropriately positioned in all five patients, with immediate post-operative angiography showing good valve shape and position. The surgeries were all marked successfully completed with no paravalvular leakage or regurgitation. All patients recovered well and were discharged the day after the surgery.

One specific case involved an 85-year-old female diagnosed with moderate aortic regurgitation, severe stenosis, moderate mitral regurgitation, and moderate tricuspid regurgitation. The surgical team decided to perform a Transcatheter Aortic Valve Implantation procedure due to the patient’s small left ventricular cavity, challenges associated with placing a stiff guidewire, and the potential risk of the guidewire falling out of the left ventricle during instrument exchange. This was done using the VitaFlow Liberty® valve (27 mm), along with the DSR27 electrically retrievable delivery system.

Postoperative angiography revealed an optimal valve shape and position without paravalvular leak or regurgitation, confirming the success of the procedure as well as facilitating a good recovery and discharge of the patient the day following the surgery.

Dr Ole De Backer commented: “The overall release process of VitaFlow Liberty® is notably stable, ensuring precise positioning. This stability is especially crucial in patients with a small heart ventricle, where VitaFlow Liberty® consistently achieves stable and precise deployment, fully demonstrating its distinct advantages. We look forward to its positive impact on a broader patient population following CE certification.”

VitaFlow Liberty® has entered six countries, namely China, Argentina, Colombia, Thailand, Russia, and Indonesia. Currently, its CE registration has made progressive achievements and is expected to be approved in the near future. The successful completion of five clinical implantations of VitaFlow Liberty® in Denmark marks a significant milestone in the pre-market clinical trials of this product in Europe.

About MicroPort® CardioFlow

Founded in Shanghai in 2015, MicroPort CardioFlow Medtech Corporation (“MicroPort® CardioFlow”, stock code: 02160.HK) is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. The Company’s self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty® is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, the Company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies and surgical accessories via independent development and collaboration with global partners. At MicroPort® CardioFlow, we strive to provide total solutions for structural heart diseases, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.cardioflowmedtech.com.